Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells

  • Max-Philipp Stenner,
  • Anne Waschbisch,
  • Dorothea Buck,
  • Sebastian Doerck,
  • Hermann Einsele,
  • Klaus V. Toyka,
  • Heinz Wiendl
  • Article
  • Metrics
  • Comments
  • Media Coverage

The authors would like to disclose the following Competing Interests: Dr. Wiendl has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Teva Pharmaceutical Industries Ltd.; has served/serves as a consultant for Merck Serono, Medac, Inc., Sanofi-Aventis/Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Novartis, and Novo Nordisk; and receives research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Novo Nordisk. The study was partly supported by funds from BiogenIdec, the manufacturer of the monoclonal antibody Natalizumab (Tysabri).

Citation: Stenner M-P, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, et al. (2010) Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells. PLoS ONE 5(12): 10.1371/annotation/d0ea7ce8-836e-428d-bdfa-5d07bc1b3af2. https://doi.org/10.1371/annotation/d0ea7ce8-836e-428d-bdfa-5d07bc1b3af2

Published: December 28, 2010

Copyright: © 2010 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing interests: No competing interests declared.